364 related articles for article (PubMed ID: 26981247)
1. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Ranki T; Pesonen S; Hemminki A; Partanen K; Kairemo K; Alanko T; Lundin J; Linder N; Turkki R; Ristimäki A; Jäger E; Karbach J; Wahle C; Kankainen M; Backman C; von Euler M; Haavisto E; Hakonen T; Heiskanen R; Jaderberg M; Juhila J; Priha P; Suoranta L; Vassilev L; Vuolanto A; Joensuu T
J Immunother Cancer; 2016; 4():17. PubMed ID: 26981247
[TBL] [Abstract][Full Text] [Related]
2. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8
Ranki T; Joensuu T; Jäger E; Karbach J; Wahle C; Kairemo K; Alanko T; Partanen K; Turkki R; Linder N; Lundin J; Ristimäki A; Kankainen M; Hemminki A; Backman C; Dienel K; von Euler M; Haavisto E; Hakonen T; Juhila J; Jaderberg M; Priha P; Vassilev L; Vuolanto A; Pesonen S
Oncoimmunology; 2014 Nov; 3(10):e958937. PubMed ID: 25941579
[TBL] [Abstract][Full Text] [Related]
3. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
Kuryk L; Møller AW; Garofalo M; Cerullo V; Pesonen S; Alemany R; Jaderberg M
J Med Virol; 2018 Oct; 90(10):1669-1673. PubMed ID: 29797583
[TBL] [Abstract][Full Text] [Related]
4. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Shoushtari AN; Olszanski AJ; Nyakas M; Hornyak TJ; Wolchok JD; Levitsky V; Kuryk L; Hansen TB; Jäderberg M
Clin Cancer Res; 2023 Jan; 29(1):100-109. PubMed ID: 36112545
[TBL] [Abstract][Full Text] [Related]
5. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
Kuryk L; Møller AW; Jaderberg M
Oncoimmunology; 2019; 8(2):e1532763. PubMed ID: 30713786
[TBL] [Abstract][Full Text] [Related]
6. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8
Vassilev L; Ranki T; Joensuu T; Jäger E; Karbach J; Wahle C; Partanen K; Kairemo K; Alanko T; Turkki R; Linder N; Lundin J; Ristimäki A; Kankainen M; Hemminki A; Backman C; Dienel K; von Euler M; Haavisto E; Hakonen T; Juhila J; Jäderberg M; Priha P; Vuolanto A; Pesonen S
Oncoimmunology; 2015 Jul; 4(7):e1017702. PubMed ID: 26140248
[TBL] [Abstract][Full Text] [Related]
7. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
Ponce S; Cedrés S; Ricordel C; Isambert N; Viteri S; Herrera-Juarez M; Martinez-Marti A; Navarro A; Lederlin M; Serres X; Zugazagoitia J; Vetrhus S; Jaderberg M; Hansen TB; Levitsky V; Paz-Ares L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37661097
[TBL] [Abstract][Full Text] [Related]
8. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
9. Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy.
Saffarzadeh N; Foord E; O'Leary E; Mahmoun R; Birkballe Hansen T; Levitsky V; Poiret T; Uhlin M
J Transl Med; 2024 Mar; 22(1):250. PubMed ID: 38454393
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
Fakih M; Harb W; Mahadevan D; Babiker H; Berlin J; Lillie T; Krige D; Carter J; Cox C; Patel M; Parfitt L; Powell M; Rosen L
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094988
[TBL] [Abstract][Full Text] [Related]
11. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
12. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
13. Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Kuryk L; Vassilev L; Ranki T; Hemminki A; Karioja-Kallio A; Levälampi O; Vuolanto A; Cerullo V; Pesonen S
PLoS One; 2017; 12(8):e0182715. PubMed ID: 28796812
[TBL] [Abstract][Full Text] [Related]
14. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
[TBL] [Abstract][Full Text] [Related]
16. Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models.
Kuryk L; Møller AW
Mol Ther Oncolytics; 2023 Mar; 28():158-170. PubMed ID: 36816748
[TBL] [Abstract][Full Text] [Related]
17. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
Pesonen S; Diaconu I; Kangasniemi L; Ranki T; Kanerva A; Pesonen SK; Gerdemann U; Leen AM; Kairemo K; Oksanen M; Haavisto E; Holm SL; Karioja-Kallio A; Kauppinen S; Partanen KP; Laasonen L; Joensuu T; Alanko T; Cerullo V; Hemminki A
Cancer Res; 2012 Apr; 72(7):1621-31. PubMed ID: 22323527
[TBL] [Abstract][Full Text] [Related]
19. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
20. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
